Article Text

Download PDFPDF
Abatacept for treatment-resistant juvenile idiopathic arthritis: a withdrawal trial

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Abatacept is a selective inhibitor of T cell activation. A fully human fusion protein consisting of the extracellular domain of cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) together with a modified Fc portion of human IgG1, it competitively binds to CD80 or CD86, inhibiting T cell activation and potentially affecting cytokine production as well as cellular aspects of autoimmunity. Abatacept is effective in treatment-resistant rheumatoid arthritis in adults and now a multicentre trial in Europe, Latin America and the USA (Nicolino Ruperto and colleagues. Lancet 2008;372:383–91; see also Comment article, ibid: 348–50) has shown that it …

View Full Text